NeRRe Therapeutics is a UK based clinical-stage company developing a unique portfolio of neurokinin (NK) -1 receptor antagonists for the treatment of common debilitating conditions caused by neuronal hypersensitivity.

Find Out More

Our Belief

We believe that the NK-1 receptor system presents one of the most exciting yet clinically under-exploited neuropeptide target classes, which has huge potential for a broad range of indications to provide truly innovative treatments to meet medical unmet needs.

Our Focus

NeRRe's ambition is to unlock the significant potential of its full pipeline in particular to progress orvepitant to Phase 3 ready. The NeRRe focus is on developing novel treatments to address common, chronic and debilitating conditions that affect millions of people around the world on a daily basis.

Exploration

In keeping with our ambition for this target class we are keen to explore opportunities to further develop the other high-quality NK-1 receptor antagonists in our pipeline to enable the full therapeutic promise of this neuropeptide receptor system to be realised.


Find Out More

Latest News

4
Dec 17

Mary Kerr CEO NeRRe Therapeutics guest speaker at a recent Labiotech meeting in London

Mary Kerr CEO NeRRe Therapeutics guest speaker at a recent Labiotech meeting in London  

read more
4
Dec 17

Say Hello to the Top 14 Female Entrepreneurs in European Biotech

Say Hello to the Top 14 Female Entrepreneurs in European Biotech

read more
27
Sep 17

NeRRe Therapeutics appoints Andrew Kay as Chairman of the Board

Extensive development & commercial expertise to guide company growth.

read more

Get In Touch

For general, media or partnership enquiries, get in touch using the form below:

Your Name (required)

Your Email (required)

Your Message